Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

B.C. Cho; A. Luft; J.A. Alatorre Alexander; S. Lucien Geater; K. Laktionov; K. Sang-We; G. Ursol; M. Hussein; L. Lim Farah; C.T. Yang; L.H. Araujo; H. Saito; N. Reinmuth; Z. Lai; H. Mann; X. Shi; S. Peters; E.B. Garon; T.S.K. Mok; M.L. Johnson

doi:10.1016/j.annonc.2022.10.365

YUHSpace

BROWSE

0 131

Cited 0 times in

Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

Authors: B.C. Cho ; A. Luft ; J.A. Alatorre Alexander ; S. Lucien Geater ; K. Laktionov ; K. Sang-We ; G. Ursol ; M. Hussein ; L. Lim Farah ; C.T. Yang ; L.H. Araujo ; H. Saito ; N. Reinmuth ; Z. Lai ; H. Mann ; X. Shi ; S. Peters ; E.B. Garon ; T.S.K. Mok ; M.L. Johnson